TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04305210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 PMPBB3
Description: In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-florbetapir
Description: 18F-florbetapir
Study: NCT03707821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A TEST Lens
Description: JJVC Investigational Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A CONTROL Lens
Description: Acuvue Oasys
Study: NCT03409809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Technical Assistance
Description: Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training, Tech. Assistance, Quality Assurance/Improvement
Description: Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability.
Study: NCT01432444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole (Abilify®) IM Depot Injection
Description: 400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013.
Study: NCT01353729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg zanamivir + moxifloxacin placebo
Description: zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 mg zanamivir + moxifloxacin placebo
Description: zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanamivir placebo + moxifloxacin placebo
Description: zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanamivir placebo + 400 mg moxifloxacin
Description: moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
Study: NCT01490021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS/Active TBS
Description: A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS/Placebo TBS
Description: rTMS/Placebo TBS
Study: NCT02439957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Study: NCT01404273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation/Relaxation Response Training
Description: 1 hour weekly sessions with 20 min daily home practice for 6 weeks
Study: NCT03789396

Intervention type: OTHER
Intervention: Targeted Normoxia (oxygen saturation 90-96%)
Description: The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation

Intervention type: OTHER
Intervention: Usual Care Oxygenation
Description: The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
Study: NCT00546104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
Study: NCT03127046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac and Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac and Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac and Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac and Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac and Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac and Esomeprazole
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
Study: NCT01551901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal fusion
Description: Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
Study: NCT02281773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 498306 50 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 498306 25 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 10 mg QD
Study: NCT02554695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous saline injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: single subcutaneous injection of denosumab 60 mg
Study: NCT00293215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-Indium-CMD-193
Description: 111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-Indium-CMD-193
Description: 111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMD-193
Description: CMD-193 was administered as an IV infusion over 60 (± 5) minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMD-193
Description: CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
Study: NCT04284358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology integrated instruction neuromuscular training warm-up workshop
Description: Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
Study: NCT02318875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kritech administration
Description: 300mg/day (1 capsule) during 12 weeks; oral ingestion
Study: NCT02439281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
Study: NCT01069757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197 and Erlotinib
Description: Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
Study: NCT00889005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Based Cognitive Behavioral Therapy
Description: Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
Study: NCT00003249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxyamidotriazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Study: NCT00243035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00800644

Intervention type: PROCEDURE
Intervention: CT or MRI + Blood Test
Description: During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover.
Study: NCT03532347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNA needle (Beacon)
Description: Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
Study: NCT01577316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Description: 2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Description: 2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus.
Study: NCT00331721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enecadin
Description: Dose escalating

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04653792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: 75 mg capsule

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg
Study: NCT00779909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
Study: NCT03638375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
Description: During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
Description: During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks.
Study: NCT00740675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Medication Reconciliation
Description: The post-discharge medication reconciliation module has the following features:~1. Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~2. Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~3. Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists).
Study: NCT01737905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine HFA-MDI (E004)
Description: Single dose 125 mcg/inhalation, 2 inhalations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-HFA
Description: Single dose 0 mcg/inhalation, 2 inhalations
Study: NCT02678533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
Study: NCT03896503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT01734044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin (rhTPO); dexamethasone
Description: Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
Study: NCT03868501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-back task
Description: All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-back task
Description: All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
Study: NCT02169596

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Blood tests taken for flow cytometry

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Blood tests taken for flow cytometry

Intervention type: OTHER
Group type: OTHER
Intervention: EndoPAT - endothelial assessment

Intervention type: OTHER
Group type: OTHER
Intervention: EndoPAT - endothelial assessment
Study: NCT03231553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MiQuit text message support programme
Description: MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
Study: NCT01155050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tele-health Home Monitoring
Description: Daily tele-health monitoring data will be collected from randomized participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TrestleTree Telephone Coaching
Description: Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
Study: NCT02439281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
Study: NCT01984541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Artemisia vulgaris
Description: Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study: NCT03253991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Description: ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
Study: NCT00362063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone (Nutropin)
Description: growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
Study: NCT01155050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tele-health Home Monitoring Plus Trestle Telephone Coaching
Description: Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
Study: NCT02318875

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo adminstration
Description: 1 placebo capsule per day during 12 weeks; oral ingestion